Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef
| DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2005 |
| Descrizione fisica | 1 online resource (277 p.) |
| Disciplina | 616.07/96 |
| Altri autori (Persone) | SchleefM (Martin) |
| Soggetto topico |
DNA vaccines
Gene therapy Immunotherapy |
| ISBN |
1-280-85409-X
9786610854097 3-527-60753-6 3-527-60700-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures
2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 5.3 Nucleic Acid Delivery - How? |
| Record Nr. | UNINA-9910876820303321 |
| Weinheim, : Wiley-VCH, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Immunogenomics and human disease / / [edited by] Andras Falus
| Immunogenomics and human disease / / [edited by] Andras Falus |
| Pubbl/distr/stampa | Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley, c2006 |
| Descrizione fisica | 1 online resource (558 p.) |
| Disciplina | 616.07/96 |
| Altri autori (Persone) | FalusAndras |
| Soggetto topico | Immunogenetics |
| ISBN |
1-280-41112-0
9786610411122 0-470-03409-2 0-470-03324-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Immunogenomics and Human Disease; Contents; Preface; List of Contributors; 1 Genotyping methods and disease gene identification; 1.1 Introduction; 1.2 Genotyping of single-nucleotide polymorphisms; 1.3 Methods for interrogating SNPs; 1.4 Analysis formats; 1.5 The current generation of methods for SNP genotyping; 1.6 The next generation; 1.7 Classical HLA typing; 1.8 MHC haplotypes; 1.9 Molecular haplotyping; 1.10 Microhaplotyping; 1.11 MHC and disease associations; 1.12 Conclusions; Acknowledgements; References
2 Glycomics and the sugar code: primer to their structural basis and functionality2.1 Introduction; 2.2 Lectins as effectors in functional glycomics; 2.3 Galectins: structural principles and intrafamily diversity; 2.4 Ligand-dependent levels of affinity regulation; 2.5 Perspectives for galectin-dependent medical applications; 2.6 Conclusions; References; 3 Proteomics in clinical research: perspectives and expectations; 3.1 Introduction; 3.2 Proteomics: tools and projects; 3.3 Discussion; 3.4 Concluding remarks; Acknowledgements; References 4 Chemical genomics: bridging the gap between novel targets and small molecule drug candidates. Contribution to immunology4.1 Introduction of chemical genomics: definitions; 4.2 Chemical microarrays; 4.3 Small molecule and peptide probes for studying binding interactions through creating a covalent bond; 4.4 Photochemical proteomics; 4.5 General aspects of photoaffinity labelling; 4.6 Photoreactive probes of biomolecules; 4.7 Application to the immunobiology of living cells; 4.8 Multifunctional photoprobes for rapid analysis and screening; 4.9 Advanced application to functional proteomics 4.10 SummaryReferences; 5 Genomic and proteomic analysis of activated human monocytes; 5.1 Primary human monocytes, as a model system; 5.2 Transcriptional profiling of activated monocytes; 5.3 Functional genomics; 5.4 Proteomic analysis of activated human monocytes; References; 6 Bioinformatics as a problem of knowledge representation: applications to some aspects of immunoregulation; 6.1 Introduction; 6.2 Sequences and languages; 6.3 Three-dimensional models; 6.4 Genomes, proteomes, networks; 6.5 Computational tools; 6.6 Information processing in the immune system; 6.7 Concluding remarks References7 Immune responsiveness of human tumours; 7.1 Introduction; 7.2 Defining tumour immune responsiveness; 7.3 Studying immune responsiveness in human tumours; 7.4 Immune responsiveness in the context of therapy; 7.5 The spatial dimension in the quest for the target; 7.6 Studying the receiving end - tumour as an elusive target for immune recognition; 7.7 The role of the host in determining immune responsiveness; 7.8 Concluding remarks; References; 8 Chemokines regulate leukocyte trafficking and organ-specific metastasis; 8.1 Chemokines and chemokine receptors 8.2 Chemokine receptors in the organ-specific recruitment of tumour cells |
| Record Nr. | UNINA-9910877894803321 |
| Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||